- Home
- AVTX vs PMVP Comparison
AVTX vs PMVP Comparison
Compare AVTX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | PMVP |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 66.0M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVTX | PMVP |
|---|---|---|
| Price | $18.08 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $32.29 | $5.00 |
| AVG Volume (30 Days) | ★ 325.7K | 263.9K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $0.81 |
| 52 Week High | $20.72 | $1.84 |
Technical Indicators
Market Signals| Indicator | AVTX | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 49.35 |
| Support Level | $18.58 | $1.21 |
| Resistance Level | $19.97 | $1.27 |
| Average True Range (ATR) | 1.29 | 0.06 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 27.60 | 77.78 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.